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Abstract
Human embryonic germ cells (EGCs) provide a powerful model for identifying molecules involved in the pluripotent state
when compared to their progenitors, primordial germ cells (PGCs), and other pluripotent stem cells. Microarray and
Principal Component Analysis (PCA) reveals for the first time that human EGCs possess a transcription profile distinct from
PGCs and other pluripotent stem cells. Validation with qRT-PCR confirms that human EGCs and PGCs express many
pluripotency-associated genes but with quantifiable differences compared to pluripotent embryonic stem cells (ESCs),
induced pluripotent stem cells (IPSCs), and embryonal carcinoma cells (ECCs). Analyses also identified a number of target
genes that may be potentially associated with their unique pluripotent states. These include IPO7, MED7, RBM26, HSPD1, and
KRAS which were upregulated in EGCs along with other pluripotent stem cells when compared to PGCs. Other potential
target genes were also found which may contribute toward a primed ESC-like state. These genes were exclusively up-
regulated in ESCs, IPSCs and ECCs including PARP1, CCNE1, CDK6, AURKA, MAD2L1, CCNG1, and CCNB1 which are involved in
cell cycle regulation, cellular metabolism and DNA repair and replication. Gene classification analysis also confirmed that the
distinguishing feature of EGCs compared to ESCs, ECCs, and IPSCs lies primarily in their genetic contribution to cellular
metabolism, cell cycle, and cell adhesion. In contrast, several genes were found upregulated in PGCs which may help
distinguish their unipotent state including HBA1, DMRT1, SPANXA1, and EHD2. Together, these findings provide the first
glimpse into a unique genomic signature of human germ cells and pluripotent stem cells and provide genes potentially
involved in defining different states of germ-line pluripotency.
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Introduction
Primordial germ cells (PGCs) are unipotent progenitors of
sperm and egg which retain an innate ability to generate
pluripotent stem cells in vivo, called embryonal carcinomas
(ECCs), and in vitro, known as embryonic germ cells (EGCs). It
is unknown whether mechanisms similar to those involved in the
generation of these cells are also involved in maintaining the
pluripotent status of other stem cells such as embryonic stem cells
(ESCs) and induced pluripotent stem cells (IPSCs). In this study,
the first genome wide assessments of human PGCs and EGCs
were performed and compared with other pluripotent ESCs,
IPSCs and ECCs.
PGCs are unipotent in that they are lineage-restricted to
become germ cells. They do not exhibit self-renewal and do not
survive past one week under standard tissue culture conditions [1].
In the mouse, it is known that PGCs are derived from a region of
the epiblast that mainly gives rise to the extra-embryonic
mesoderm. In humans, PGCs first appear between the third and
fourth week post-fertilization in the endoderm of the dorsal wall of
the yolk sac, near the allantois, then proceed to migrate through
the hindgut during the fourth week and dorsal mesentery in the
fifth week to reach the genital ridge [2–4].
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pluripotent stem cells. EGCs are pluripotent stem cells derived
from PGCs in cell culture using specific growth factors and media
formulations. The term EGCs, was given by Donovan et al. [5,6]
who derived them from mouse PGCs, in order to distinguish them
from ESCs. Since then, a handful of other laboratories have also
reported the generation of human EGC lines [7–11]. ECC lines
are another source of pluripotent cells that are cultured from adult
teratocarcinomas from which there is genetic, immunological, and
morphological evidence suggesting a PGC origin [12]. Lastly,
IPSCs can be generated from PGCs by lentiviral transduction of
pluripotent regulators similar to those used to generate IPSCs from
somatic cells [13–18].
EGCs share the general properties of pluripotent stem cells
including unlimited self-renewal and the ability to give rise to cells
that represent all three embryonic germ layers. In contrast, EGCs
are unlike any other pluripotent stem cell as they are derived from
differentiated cells without IPSC-like targeted genetic manipula-
tions and unlike ECCs, maintain a stable karyotype. Furthermore,
while human EGCs can generate a variety of cell-types
representative of the three germ layers in vitro, they do not form
teratomas in vivo like their mouse EGC counterparts. Therefore,
EGCs may exist in a uniquely, partial, or intermediate pluripotent
state. As such, comparisons between EGCs and PGCs with other
pluripotent stem cells provide a powerful model to identify factors
that are associated with different states of pluripotency.
Distinct states of pluripotency have been revealed by several
laboratories which have shown that pluripotent stem cells exhibit
differences in their clonal or self-renewing and differentiating
capacities [19–22]. For instance, mouse ESCs and IPSCs in the
‘‘naı ¨ve state’’ demonstrate single cell clonal ability, rounded colony
morphology, and are not dependent on FGF2 and TGFb/Activin
signaling. In contrast, conventional human ESCs and IPSCs and
mouse epiblast-derived stem cells exist in a ‘‘primed state’’ of
pluripotency exhibiting flattened colony morphology, insufficient
clonal expansion, and a dependence on FGF2 and TGFb/Activin
signaling. These differences in pluripotent states have been
attributed to species differences as well as the developmental state
of the stem cell origin and yet they are inter-convertible depending
on the cell culture environment. For instance, the primed state of
human ESCs and IPSCs was shown to be convertible to the naı ¨ve
mouse ESC-like state given the appropriate factors in cell culture
[22]. It has also been shown that mouse EGCs will behave similar
to the naı ¨ve state of mouse ESCs under similar culture conditions
[23]. However, it remains unknown whether human EGCs could
also be converted to a naive state. Indeed, there is considerable
interest in deciphering the range of multiple pluripotent states in
human cells as they could be utilized to partition out mechanisms
that regulate distinct attributes of the pluripotent phenotype.
Currently, the pluripotent state of conventional human EGCs
is unknown. For instance, like human ESCs, conventional human
EGCs express SSEA3, SSEA4 and TRA antigens, TRA-1-60
and TRA-1–80, which are inefficient at clonal expansion and
require FGF2 in cell culture [8,24]. However, similar to mouse
ESCs, human EGCs share rounded morphology, express SSEA1
and require LIF for their survival. Given that human EGCs
share features in common with both mouse ESCs and human
ESCs, it is likely that conventional EGCs fall in their own unique
state of pluripotency. Therefore, the following study provides
new insight into this question and reveals the genomic signature
of EGCs which will identify new candidate genes for regulating
pluripotency.
Comparisons between EGCs and PGCs will also help establish
a unique signature of human PGCs which have not been
demonstrated before while also providing further insight into
whether ESCs originate from a PGC origin. Indeed, several lines
of evidence suggest that PGCs and ESCs may originate from an
early germ cell progenitor [25–27]. For instance, several reports
have demonstrated that mouse ESCs express genes associated
with immature male and female germ cells such as Stella, deleted in
azoospermia-like (Dazl) and Fragilis [28,29]. Similarly, one study
that examined the differentiation of human ESCs into germ cells
[30], detected the expression of eight genes characteristic of early
germ cells in ESCs and none from six genes expressed by later
germ cells. Most significantly, this study demonstrated gene
expression of DAZL by ESCs but not by human inner cell mass
(ICM). In a recent study, Scholer et al. [31] demonstrated
significant similarities in gene profiles between mouse PGCs and
ESCs. Despite these relevant studies, it is largely unknown how
human PGCs resemble ESCs at the molecular level compared to
other PGC-derived stem cells.
Global expression analyses have been extensively performed to
examine the molecular signature of human pluripotent stem cells.
These studies have characterized gene expression profiles of
human ESC, IPSC, and ECC lines using microarray and other
high-throughput analyses in attempts to identify candidates
involved in self-renewal or pluripotency [32–37]. In addition to
comparisons with mouse stem cells, a meta-analysis performed by
Assou et al., [38] provides further statistical significance to genes
that have been found enriched in ESCs by these studies.
Importantly, the meta analysis revealed the ability of the
microarray studies to consistently reveal patterns of similarities
and differences in gene-expression patterns among human ESC
lines including high levels of OCT4, SOX2, and NANOG
expression in human ESCs, three factors which are critical for
maintaining pluripotency in mouse [39–41] and human stem
cells [42]. Other genes associated with pluripotency are also
found including UTF1, REX1, FOXD3 and members of the
FGF2, MAPK-ERK, TGFB/activin/nodal, Wnt/b-catenin and
Akt/PkB signaling pathways. Together this data demonstrates
the efficacy of genomic profiling for determining the ‘‘stem-cell’’
orchestra and provide a foundation for further comparisons of
these cells with PGCs and EGCs. Two other studies have also
reported on the genomic profiles of PGCs for the purpose of
identifying mouse unipotent PGC specific genes that would
distinguish them from mouse ESCs [31,43]. Scholer and
colleagues [31] revealed 4 new unipotent PGC specific genes
that are highly conserved in mouse and human while Mise et al.
[43] demonstrated that mouse EGCs were more similar to ESCs
compared to mouse PGCs and adult germ line derived stem
cells.
In this study, we conduct the first genome-wide comparison
study of human PGCs and EGCs with a number of diverse
pluripotent stem cell types including ESCs, ECCs, and IPSCs.
Genomic analyses classified these cell types into three distinct
groups, 1) PGCs, 2.) EGCs, and 3.) IPSCs, ESCs ECCs, that
reflected their developmental potential. These comparisons
included qualitative and quantitative differences in known
pluripotent associated gene expression as well as revealing a novel
signature for human EGCs. Thus, these findings provide
important information for identifying potential mechanisms
required for PGC reprogramming into the pluripotent state.
Comparisons between human PGCs and ESCs will also help
facilitate the identification of factors associated with germ line
development and may help establish factors related to a common
germ cell progenitor potentially shared between these cell types.
Genome-Wide Profiling of Human Germline Stem Cells
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Gene expression was studied in five different cell types including
PGCs, EGCs, ECCs, IPSCs, and ESCs (Figure 1). In contrast to
PGCs, which were directly isolated from tissue, cell lines analyzed
in this study were isolated between passage 15 to 27. ECC and
ESC lines were XY, while PGCs, EGCs, and IPSCs represented
both XX and XY genotypes. PGCs were diploid at this stage in
development as previously described [24,44]. Both EGC and
IPSC lines were derived from SSEA1+ sorted PGCs and IPSCs
generated using lentiviral integration of SOX2, OCT4 and MYCN
genes into PGCs. Details of the cells used in this study are
described in Table S2 in Supplementary Material.
Quantitative RT-PCR Validation of known Pluripotent and
Germ Cell Associated Genes in PGCs, EGCs and
Pluripotent Stem Cells
Real-time quantitative RT-PCR analysis (Figure 2) was used to
validate the expression of genes known as unique signatures of
germ cells and the pluripotent state in our study populations. This
was performed on 3 independent cell lines from each group
different from those analyzed by microarray analysis. Figure 2
shows data for OCT4, SOX2, NANOG, and DNMT3B from 2–3
independent biological specimens or cell cultures as in the case of
ECCs, ESCs, and a human foreskin-derived fibroblast line, HFF1,
and each experiment was performed in triplicate. HFFs were used
to study relative expression across all groups. Results showed that
PGCs expressed higher levels of all pluripotent stem cell genes
compared to fibroblasts except DNMT3B. Furthermore, the
expression of all pluripotent genes was considerably higher in
ESCs, IPSCs, and ECCs compared to the PGCs. Likewise, EGCs
expressed elevated levels of SOX2 similar to ESCs, IPSCs, and
ECCs. In fact, this significant increase in SOX2 compared to PGCs
in addition to the slightly elevated levels of OCT4 and NANOG
expression in EGCs is the most distinguishing feature between
these two populations. Although protein levels were not measured
in this study, it has been previously reported and shown in our
observations that the SOX2 protein is not significantly detectable
in human PGCs, unlike mouse PGCs [45]. Therefore, the results
of qRT-PCR suggests that the regulation of the SOX2 protein in
human PGCs is at the transcriptional level and that regulators of
SOX2 gene expression may play a significant role in PGC
reprogramming to EGCs. These results are also consistent with
microarray and hierarchical analyses which distinguish SOX2
expression as a unique signature of the ESC, IPSC, and ECC
group compared to PGCs. Another interesting observation was the
down regulation of DNMT3B in both PGCs and EGCs compared
to ESCs, IPSCs, and ECCs. This is consistent with the role of
DNMT3B in DNA methylation for defining pluripotency in
human cells.
Pair-wise Comparisons of Gene Expression Profiles of
PGCs and Pluripotent Stem Cell Lines
To explore the similarities in gene expression profiles, pair-wise
comparisons and Pearson’s correlations were performed
(Table 1). As expected, populations within the same cell types
revealed the strongest correlations in gene expression patterns
ranging from 0.85–0.99. Variability within groups was the least
with IPSCs or ECCs lines which showed the highest correlations
within their respective groups at 0.99, P,0.001 each, while PGCs
were 0.96 and EGCs ranged from 0.85–0.94. Several possibilities
may contribute to the variation found in and among these stem
cell lines including the contribution of sex-linked genes and by the
passage of time in culture. For instance, when different types of
pluripotent stem cell lines are compared, the highest correlations
are seen between ECC lines and ESCs (ranging from 0.93–0.94).
These lines are both XY and similar in subculture passages.
However, ECCs are distinct in their tumorigenic properties from
other ESC-like stem cells in that they are malignant cancer stem
cells. Nonetheless, the malignant nature of ECCs is not a major
contributing factor underlying the close association seen between
ESCs. Likewise, it is clear that IPSCs though comprised of both
sexes and of an earlier passage than ESCs and ECCs are more
similar to male ECCs (0.90–0.91) and ESCs (0.86–0.88) than to
either PGCs (.78–.83) or EGCs (.77–.89). This data is consistent
with the pluripotent nature of the IPSCs. Thus, it appears that
while sex and subculture passages may contribute to some of the
differences seen across cell lines, the close associations found
among these cells can be primarily contributed by their pluripotent
state.
The expression profiles of EGCs shows the highest similarity to
PGCs (,0.89) compared to ECCs, IPSCs, and ESCs (averaging
between 0.80–0.82). This is expected as EGCs are derived from
PGCs. While the IPSCs and ECCs were also derived by PGCs, it
has been hypothesized that ESCs are also derived from an early
PGCs progenitor present in the inner cell mass. These results
suggest the EGCs may represent a distinct state of pluripotency
consistent with differences seen between EGCs and other
pluripotent stem cells grown under traditional culturing methods.
For instance, human EGCs, derived under these conditions are
more unstable, in that they spontaneously differentiate in culture.
EGCs also do not form teratomas in immunocompromised mice
even though they can generate a variety of cell types in vitro. Thus,
the expression profile of EGCs compared to their unipotent
progenitor and other pluripotent stem cells may be indicative of
the EGCs unique pluripotent state. Additionally, it would be
important to delineate the fraction of genes that may be affected
by these cell culturing attributes. Such examination could benefit
from the comparisons performed herein among these cell types.
Multivariate Comparisons of Gene Expression Profiles of
PGCs and Pluripotent Stem Cells
Global gene expression patterns of PGCs, EGCs, ECCs, IPSCs,
and ESCs were analyzed using PCA, which reduces redundancies
in variability within high dimensional array data into a smaller
number of principal components. Data for PCA including log ratio
values and P-values are included in Table S3. Figure 3A shows
the plotted position of each cell population against the PC1 and
PC3 axes and Figure 3B is representative of the PC1, PC2, and
PC3 axes in three dimensional (3D) space. All three PCs
accounted for about 71% of the variation present in the entire
data set (PC1; 0.445, PC2; .164, PC3; .102). From Figure 3A a
distinguishable grouping difference can be seen between ESCs,
ECCs, and IPSCs which are grouped together and distinctly
located away from EGCs and PGCs along the PC1 and PC3 axis.
For instance, PGCs are located in the bottom left side of the PCA
plot while ECCs, IPSCs, and ESCs are shifted toward the right
along the PC1 component axis and EGCs are grouped in the
upper left corner along the PC3 axis. Thus, most of the gene
expression differences (44.5%) accounted for were along the PC1
axis and may be to the developmental state of these cells. There
was also a greater difference along the PC3 axis between EGCs
and PGCs compared to ESCs, ECCs, and IPSCs located in
between. Thus, the genes associated with the PC3 axis (constitut-
ing 10% of the variation) are likely to define differences in the
intermediate pluripotent state of EGCs that are independent of the
primed human ESC-like state. Figure 3B is a three-dimensional
plot representing signature genes of each cell type and correlates
Genome-Wide Profiling of Human Germline Stem Cells
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identify three distinguishing groups of cells which comprise 1.)
unipotent PGCs, 2.) EGCs, and 3.) primed human ESC-like stem
cells encompassing ECCs, IPSCs and ESCs.
Next, we tried to detect genes that define the characteristics of
the pluripotent stem cell and PGC groups based on the PCA
results. Because PGCs are well separated along the PC3 axis,
genes that make a large contribution to PC3 were sought using a
loading scatter plot, shown as Figure 3C. Grey dots represent
Figure 1. Phase contrast images representing different stem cells studied in gene expression analyses. (A) primordial germ cells (PGCs),
(B) embryonic germ cells (EGCs), (C) induced pluripotent stem cells (IPSCs), (D) embryonic stem cells (ESCs), and (E) embryonal carcinoma cells (ECCs).
doi:10.1371/journal.pone.0039088.g001
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shown in red. Genes represented by red circles in Figure 3C were
the most highly differentially expressed genes (1000 of 54,000, or
1.85% genes in the array) (Table S4) compared to the overall
mean across all cell lines with FDR adjusted P,0.0001. The PGC
group samples were located between lines at angles of 3.75 and
4.05 radians on the 2D PCA plot (Figure 3A), and genes mapped
in the corresponding space by blue lines in the loading scatter plot
(Figure 3C) showed elevated expression in the PGC group.
These signature genes show enhanced expression in PGCs
compared to other cell groups. Genes plotted between 2.10 and
2.80 radians (purple lines in Figure 3C) represent ‘‘EGCs
signature’’ genes. Green dotted lines represent genes upregulated
in IPSC, ESC and ECC groups located between 5.65 and 0.69
radians.
The location of the specific signature genes along the PC1 and
PC3 axis indicates that there is a clear classification or grouping
difference among the PGC, EGC, and ESC-like stem cell groups.
EGC signature genes are located in the upper half of the PC3 axis
and includes genes SRY (sex determining region Y)-box 9 (SOX9),
Figure 2. Real-time qRT-PCR analysis of several key pluripotent and germ cell associated genes in primordial germ cells and
pluripotent stem cells. OCT4, SOX2, NANOG, and DNMT3B were normalized to the beta-actin gene using the comparative CT method, and plotted
relative to the human foreskin fibroblast line, HFF1 (0 baseline) (N =3 biological samples with technical triplicates for each cell type, P,0.05).
Asterisks denote statistical significant differences in cell lines compared to PGCs.
doi:10.1371/journal.pone.0039088.g002
Table 1. Pair-wise comparisons of gene expression profiles.
EGC1 EGC2 EGC3 ESC PGC1 PGC2 ECC1 ECC2 IPSC1 IPSC2 IPSC3
EGC1 0.8997 0.8987 0.8327 0.8931 0.8560 0.8494 0.8469 0.8855 0.8846 0.8698
EGC2 0.8469 0.9399 0.8034 0.9174 0.8975 0.7709 0.7671 0.7887 0.7897 0.7669
EGC3 0.8987 0.9399 0.8295 0.9091 0.8858 0.8011 0.7983 0.8076 0.8091 0.7892
ESC 0.8327 0.8034 0.8295 0.8731 0.8372 0.9356 0.9346 0.8685 0.8712 0.8779
PGC1 0.8931 0.9174 0.9091 0.8731 0.9606 0.8363 0.8338 0.8313 0.8349 0.8220
PGC2 0.8560 0.8975 0.8858 0.8372 0.9606 0.7983 0.7958 0.7927 0.7962 0.7829
ECC1 0.8494 0.7709 0.8011 0.9356 0.8363 0.7983 0.9949 0.8993 0.8997 0.9133
ECC2 0.8469 0.7671 0.7983 0.9346 0.8338 0.7958 0.9949 0.8977 0.8992 0.9138
IPSC1 0.8855 0.7887 0.8076 0.8685 0.8313 0.7927 0.8993 0.8977 0.9958 0.9746
IPSC2 0.8846 0.7897 0.8091 0.8712 0.8349 0.7962 0.8997 0.8992 0.9958 0.9747
IPSC3 0.8698 0.7669 0.7892 0.8779 0.8220 0.7829 0.9133 0.9138 0.9746 0.9747
doi:10.1371/journal.pone.0039088.t001
Genome-Wide Profiling of Human Germline Stem Cells
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Factor 4 (KLF4) and AXL receptor tyrosine kinase (AXL) which are
significantly up-regulated in these cells. These genes may
contribute to the partially reprogrammed state of EGCs in
culture. PGC signature genes located in the lower half of the PC3
axis include hemoglobin alpha 1 (HBA1), X (inactive)-specific transcript
(XIST), testis expressed 13A (TEX13), and SPO11 meiotic protein
(SPO11). Spo11, Hba1 and Tex13 have been identified in mouse
microarrays as germ cell markers [31]. XIST is known to be down
regulated in pluripotent stem cells compared to PGCs [46]. XIST
expression was exclusively expressed by the female PGCs as
expected and represents the more differentiated state of these
unipotent progenitors compared to the female EGC and iPSC
which also included.
Genes with shared expression levels in PGCs and EGCs were
also identified and may represent a common germ cell progenitor
phenotype. For example, located in the middle of the PC3 axis,
commonly enriched genes in EGCs and PGCs included imprinted
maternally expressed transcript protein (H19), transforming growth factor beta
1 (TGFB1), integrin alpha 8 (ITGA8), insulin-like growth factor binding
Figure 3. Principal component analysis (PCA) of the expression profiles of primordial germ cells and pluripotent stem cells. (A) Two-
dimensional PCA map of cell types, comparing PC1 and PC3. (B) Three-dimensional map comparing all cell types. (C) A loading scatter plot for the
identification of signature genes. Red dots represent the top 1000 differentially genes expressed across the mean of all lines with FDR adjusted
P,0.0001. ‘‘PGC signature’’ genes include HBA1, TEX13, and SPO11 located on the lower left half of the scatter plot. In contrast, XIST was upregulated
in PGCs compared to other pluripotent stem cell lines as expected given their differentiated state. ‘‘PGC/EGC common’’ genes include H19, BGN,
ITGA8, IGFB5, MOV10L1, and TGF-B1. ‘‘EGC signature’’ genes include SOX9, KLF4, FN1, AXL, and FKBP6. ‘‘ECC, ESC, and IPSC’’ signature genes include
DPPA4, NANOG, SOX2, PIWIL2, MYCN, GDF3, and OCT4.
doi:10.1371/journal.pone.0039088.g003
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1 homolog (MOV10L1). Genes that are associated with the PC1
axis define unique differences in pluripotency between PGC,
EGC, and the primed human ESC-like groups. This is shown by
the distinct localization of known pluripotent stem cell signature
genes including NANOG, MYCN, SOX2, OCT4, and GDF3 in the
region containing ECCs, ESCs, and IPSCs.
In summary, PCA demonstrates that EGCs exhibit a unique
genetic signature from PGCs and other pluripotent stem cells
suggesting that EGCs represent a distinctive pluripotent state with
many shared features of ESCs/IPSCs and ECCs. Moreover, these
results reveal a unique set of genes which may be associated with
the pluripotent state of EGCs. Thus, it is possible that these genes
are uniquely turned on during the EGC stage of pluripotency and
then turned off toward a more naı ¨ve like state. Consequently, it
would be interesting to compare human EGCs with partially
reprogrammed IPSCs and human IPSCs and ESCs to provide
further insight into this issue.
Differences in Gene Expression Profiles between PGCs
and Pluripotent Stem Cell Lines Define Unique Genetic
Signatures of Developmental Potency
Expression analysis of PGCs with the pluripotent stem cell lines
indicated that the expression profiles of PGCs and EGCs were
significantly different from the ESC, IPSC and ECC groups. The
number of differentially expressed genes in EGCs, ESCs, IPSCs,
and ECCs compared with PGCs are shown in Table 2 and the
complete list of genes compiled in Table S5. PGCs showed higher
expression of 105 genes and significantly lower expression of 656
genes when compared to ESCs (Tables S5, Sheet 1 and 2,
respectively). Similar numbers of genes were also distinguished
when PGC gene expression was compared to either IPSCs or
ECCs. For instance, when PGC and ECC profiles were compared
132 genes were upregulated in PGCs compared to the up-
regulation of 716 genes in ECCs (Tables S5, Sheet 7 and 8,
respectively). Similarly, when PGC profiles were compared to
IPSCs, PGCs showed higher expression of 233 genes and
decreased expression of 496 genes (Tables S5, Sheet 5 and 6,
respectively). Together, this data shows that a significantly
higher number of genes are upregulated in the ESC, IPSC, and
ECC lines compared to PGCs. Upregulation of these genes may
be relevant to maintaining a primed hESC-like pluripotent state in
these lines. In contrast, fewer genes were upregulated in EGCs
compared to PGCs. (194 upregulated versus 94 down regulated
genes) (Tables S5, Sheet 3 and 4, respectively). Thus, more
genes were altered in PGCs during their reprogramming into
IPSCs, ESCs, and ECCs than EGCs potentially signifying a
unique developmental state for human EGCs.
Specifically, when PGCs are compared to all lines including
EGCs, the number of differentially expressed genes is reduced
approximately 15 fold. In this case, 20 genes were detected that
were upregulated in all four stem cell lines compared to PGCs
versus 332 genes in ESCs, IPSCs, and ECCs with EGCs excluded
(Tables S5, Sheet 10 and 12, respectively). Likewise, fewer
genes are also found upregulated in PGCs when EGC profiles
were combined with the analysis, i.e. 49 genes are upregulated in
PGCs compared to all pluripotent lines compared to the 70 genes
upregulated in PGCs when EGCs are not included (Tables S5,
Sheet 9 and 11, respectively). Therefore, the comparisons
with EGCs identified a reduced number of candidate genes which
may be associated with the conversion of PGCs into the
pluripotent state.
Notably, when PGCs were compared to all lines including
EGCs, 20 novel associated genes were discovered that were up
regulated in the stem cell lines. These included Importin 7 (IPO7),
mediator complex subunit 7 (MED7), RNA binding motif protein 26
(RBM26), and heat shock 60 kDa protein 1 (HSPD1). In addition,
multiple genes with known or suspected roles in self-renewal or
‘‘stemcellness’’ were highly-up-regulated in ESCs, IPSCs, and
ECCs compared to human PGCs. These included SOX2, cyclin E1,
(CCNE1), cyclin B1 (CCNB1), and cyclin dependent kinase 6( CDK6).
Signature Genes Demonstrate Unique Trends in their
Expression Pattern Across Lines
Expression patterns of representative genes identified by the
PCA as significantly upregulated are shown in Figure 4. PGC
signature genes included HBA1, DMRT1, TEX13, and meiotic
protein SPO11. PGCs do not form tumors while ECCs form
malignant carcinomas, IPSCs form benign teratomas, and human
EGCs form cyst like structures, not teratomas. Therefore,
differential upregulation of expressed genes in ECCs which
include sal-like 4 (SALL4), growth differentiation factor 3 (GDF3), v-
myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN),
and piwi-like 2 (PIWIL2) may be indicative of their oncogenic as
well as their pluripotent properties in these stem cells. Indeed, all
four genes have been associated with tumorigenicity, and they
demonstrate a similar pattern of expression that was lowest in
EGCs and IPSCs compared to ESCs.
In comparison, genes identified in the top 1000 differentially
expressed genes transcripts of EGCs included FN1, FKBP6, AXL,
and SOX9. FN1, AXL, and SOX9 demonstrated a similar pattern of
expression across all lines and have been shown by others to be
over expressed in germ cell tumors [47–50]. In contrast, FKBP6
demonstrated a different pattern in which it was uniquely
upregulated in EGCs and PGCs but down regulated in ESCs,
IPSCs, and ECCs. In mouse studies, this marker was significantly
down regulated in both germline stem cells and ESCs compared to
mouse PGCs, and therefore concluded to be a unipotent
progenitor marker of mouse PGCs. Although this trend was
similar in most of the human cell lines studied here, FKBP6 was
also elevated in EGCs. Thus, it is uncertain whether the difference
between these two studies is due to speciation or whether up
regulation of FKBP6 is uniquely upregulated in EGCs compared to
human germ line stem cells.
Interestingly, genes up regulated in IPSCs included both
proliferative and anti-proliferative responses controlling cell cycle
progression. For instance, IPSCs like other pluripotent stem cells
expressed facilitators of the cell cycle such as CCNE1, CCNB1,
CDK6 and CDK1. However, IPSCs distinguished themselves from
ESCs and ECCs by their elevated expression of known anti-
proliferative regulators phosphatidylinositol 3’-kinase receptor 3
(PIK3R3), BCL2-associated X protein (BAX) MAD2 mitotic arrest
deficient-like 1 (MAD2L1), and adenomatous polyposis coli (APC).
Previous reports have also shown similar results in IPSCs
generated from somatic cells with up-regulation of these and
other anti-proliferative factors involved in apoptosis, senescence
and/or cell-cycle arrest (reviewed in [51]). Similar to these studies,
the IPSC profiles here showed up-regulation of the apoptotic
mediated factor, BAX, and G1 cell cycle arrest facilitator,
P16INK4a (or CDKN2a). They also expressed elevated levels of
PIK3R3 which is a member of the PI3K family and interacts with
retinoblastoma protein to regulate cell proliferation and cell cycle
progression. As such over expression of PIK3R3 has been
associated with ovarian, liver, prostate and breast cancers [52].
When mutated, the tumor suppressor gene, APC, is associated with
chromosome instability and tumor progression via beta-catenin
signaling [53,54], and when normally expressed is a critical
component of cellular defense mechanisms involving cell cycle
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Together, these results support evidence in IPSCs derived from
somatic cells, which also demonstrate elevated expression of anti-
proliferative regulators such as these. Thus, it would be interesting
to validate these results and determine whether these factors are
involved in the unique signature of IPSCs as a response of their
derivation or a necessary requirement of their artificially induced
pluripotent state.
Genes up-regulated in ESCs include several interesting targets
that have shown some implications of regulating pluripotency in
mouse cells. These are shown in Figure 4 which includes deleted in
azoospermia-like (DAZL), CYCLIN G1 (CCNG1), AT rich
interactive domain 2 (JARID2), and zinc finger and SCAN
domain containing 1 (ZSCAN1). DAZL has been identified as an
early germ cell marker supporting the notion of a germ cell origin
for ESCs. In the same family as ZSCAN1, ZSCAN4 has been shown
to be critical in regulating telomerase activity and pluripotency of
mouse ESCs [58]. CYCLIN G1 has roles in cell cycle progression
and has been shown to be elevated in mouse EGCs and ESCs
[59]. More recently, JARID2 has been shown to be elevated in
mouse ESC and modulate pluripotency via polycomb regulation
[60].
Comparing Gene Expression Patterns in PGCs, EGCs and
Pluripotent Stem Cells using Hierarchical Clustering
To further examine the relationship between human PGCs and
EGCs to other pluripotent stem cell lines, signature genes were
hierarchically clustered to determine their relationship across all
cell lines. Hierarchical analyses was performed for genes that
demonstrated the highest differential expression in pluripotent
stem cells lines compared to PGCs. Approximately 60% of these
genes comprised three distinct regions of gene clusters that were
indicative of the PGC, EGC, or the ESC, IPSC and ECC groups.
The heat maps of these regions are shown in Figure 5. Consistent
with the PCA results, the highest levels of gene expression in PGCs
compared to the pluripotent stem cells consisted of a tight cluster
of several potential PGC signature genes. These genes corre-
sponded with the loading scatter plot results and are shown to be
up-regulated in Figure 5A including the HBA1, Doublesex and mab-
3 related transcription factor 1 (DMRT1), and Sperm protein associated
with the nucleus, X-linked, family member A1 (SPANXA1). These
predicted signature PGC genes were also identified in the top 1000
differentially expressed genes from PCA. A different pattern
between EGCs and PGCs is seen in Figure 5B where many of the
genes that are highly up-regulated in EGCs compared to the ESC,
IPSC, and ECC group were also elevated in PGCs, though not as
high. These included H19, IGFBP5, ITGA8, BGN and EH-domain
containing 2 protein (EHD2). These results further suggest that EGCs
still retain marks of their unipotent PGC-like state. In contrast,
KLF4, SOX9, AXL, and FN1 were uniquely upregulated in EGCs
compared to PGCs suggesting their involvement in EGC
derivation. Similar up regulation of KLF4 expression has been
demonstrated in the conversion of mouse PGCs into EGCs [31].
Cluster analyses also revealed the overall expression patterns of
potential pluripotent genes elevated in the ESCs, ECCs, and
IPSCs compared to PGC and EGCs (Figure 5C). As expected,
SOX2 was significantly elevated in the pluripotent stem cells
compared to PGCs consistent with results from PCA. Other
factors that were elevated in ESCs, ECCs, IPSCs included those
involved in cell cycle namely CCNB1, CCNE1, CDK1, CDK6,
HSPD1, ), v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
(KRAS) as well as those defined by the PCA including IPO7,
MED7, and RBM26 (Table S4).
Gene Classification and Biosystems Modeling of Potential
Pluripotent Pathways
To identify potential pathways and interpret gene relationships
distinguishing EGCs from ESCs, IPSCs and ECCs, a gene
classification approach was used by employing the Panther
Classification System and Ingenuity Pathways Analysis (IPA).
Table 2. Classification of genes differentially expressed in ESCs, EGCs, ECCs, and IPSCs versus PGCs.
Class Number of Genes Explanation Statistics
PGC vs. ESC
105 Genes up-regulated in PGCs FC.2, FDR adjusted p,0.0001
656 Genes up-regulated in ESCs FC.2, FDR adjusted p,0.0001
PGC vs. EGC
194 Genes up-regulated in PGCs FC.2, FDR adjusted p,0.0001
78 Genes up-regulated in EGCs FC.2, FDR adjusted p,0.0001
PGC vs. IPSC
233 Genes up-regulated in PGCs FC.2, FDR adjusted p,0.0001
496 Genes up-regulated in IPSCs FC.2, FDR adjusted p,0.0001
PGC vs. ECC
132 Genes up-regulated in PGCs FC.2, FDR adjusted p,0.0001
716 Genes up-regulated in ECCs FC.2, FDR adjusted p,0.0001
PGC vs. (ESC+IPSC+ECC)
70 Genes up-regulated in PGCs FC.2, FDR adjusted p,0.0001
332 Genes up-regulated in (ESC+IPSC+ECC) FC.2, FDR adjusted p,0.0001
PGC vs. (ESC+IPSC+EGC+ECC)
49 Genes up-regulated in PGCs FC.2, FDR adjusted p,0.0001
20 Genes up-regulated in (ESC+IPSC+EGC+ECC) FC.2, FDR adjusted p,0.0001
doi:10.1371/journal.pone.0039088.t002
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39088Figure 4. Identification of potential signature genes of PGCs, ECCs, EGCs, IPSCs, and ESCs. The vertical axis of each graph shows the log
ratio of the expression data relative to the population mean. (A) Genes that are up-regulated in PGCs include (A) SPO11, DMRT1, TEX13, and HBA1. (B)
Genes up-regulated in ECCs include SALL4, GDF3, MYCN, and PIWIL2. (C) Genes up-regulated in EGCs include FN1, FKBP6, AXL, and SOX9. (D) Genes up-
regulated in IPSCs include MAD2L1, PIK3R3, BAX and APC. (E) Genes up-regulated in ESCs include DAZL, CCNG1, JARID2, and ZSCAN1.
doi:10.1371/journal.pone.0039088.g004
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tion System, and IPA was used to detect molecular connections
between genes that were differentially expressed in pluripotent
stem cells compared to PGCs. Together these analyses aid in the
understanding of known genes in the context of biological
pathways, functions and cellular processes that distinguish EGCs
and PGCs from pluripotent stem cells. GO analysis shows the
distribution of different cell functions, as percentages, that are
allocated in ESCs, IPSCs and ECCs compared to EGCs
(Figure 6). Distinct differences between the allocations of
biological functions in EGCs compared to these stem cells are
found. One of the major differences is their commitment to the cell
cycle and metabolic processes. ESCs, IPSCs and ECCs allocate
11% of their functioning toward cell cycle and 33% to metabolic
Figure 5. Hierarchical clustering of potential signature genes. Gene expression levels of (A) PGC signature, (B) EGC and common PGC/EGC
signature and (C) ESC, IPSC and ECC group genes are represented in a heat map. Lists of genes corresponding to each group are on the right hand
side of the cluster tree. Order of the genes in the tables corresponds to their order in the heat map (high expression in red, log
10=.1.00; low
expression in green; log
10=,–1.00).
doi:10.1371/journal.pone.0039088.g005
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metabolic processes. This is consistent with their reduced
proliferation rates in culture. Additionally, there is a distinct
difference in the percentage effort allocated for apoptotic functions
in EGCs. Specifically, EGCs commit a significantly lower portion,
1.7%, of their cellular functions for regulating apoptosis, compared
to ESCs, IPSCs and ECCs which allocate 4.8% percent for that
same function. Taken together, these results suggest a strong role
for cell cycle and apoptotic factors in maintaining a balance in
stem cell self-renewal capacities. Another large difference exists
between the commitments of these cells to adhesion processes.
EGCs seem to allocate a larger percentage of their cellular
demand (9%) to functions relating to cell adhesion while ESCs,
IPSCs and ECCs allocate only 1.7%. This is consistent with a
primary difficulty in maintaining EGCs in culture which includes
their resilience to dispersion during subculture compared to other
pluripotent stem cells. Despite the clear differences in allocation of
biological processes existing between EGCs and pluripotent stem
cells, there are also many similarities. For example, both cells
express nearly identical percentages for transport functions,
developmental processes, and cellular component organization.
IPA software was also used to detect potential pathways that
were specifically up-regulated in pluripotent stem cells and down
regulated in PGCs. Figure 7 represents the biological relation-
ships that exist between the regulated proteins responsible for
pluripotency. Results showed that as expected the majority of
these genes were expressed at similar levels (gray) among
pluripotent stem cells and PGCs while SOX2 and FRIZZLED
were uniquely up regulated in EGCs, ESCs, IPSCs, and ECCs
compared to PGCs. Other known pluripotent regulators, NANOG
and OCT4, were also shown to be expressed but at similar levels
among groups. Most interestingly, when genes upregulated in the
pluripotent stem cells compared to PGCs was analyzed, IPA
analysis identified an integral network that appears to be
upregulated in pluripotent stem cells. Figure 8 is a graphical
representation of intersecting networks responsible for controlling
cell cycle, DNA replication, DNA repair, recombination, and cell
death in which the majority of these components were upregulated
in the ESC, IPSC and ECC group compared to PGCs. This
included cyclins CCNE1, CCNG1 and CCNB1 as well as apoptotic
and DNA repair-recombination regulators, BAX and Poly (ADP-
ribose) polymerase 1 (PARP1).
Figure 6. Classification of genes by specific molecular and biological function. (A) Biological processes up-regulated in ESCs, IPSCs, and
ECCs compared to PGCs. (B) Biological processes up-regulated in EGCs compared to PGCs. The allocation of specific biological functions in
pluripotent stem cells and EGCs are represented by percentages in the table legend.
doi:10.1371/journal.pone.0039088.g006
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ties in cell cycle regulation, KRAS and HSPD1, were upregulated in
all stem cells compared to PGCs. KRAS is a GTPase in the Ras
family and is essential in normal tissue signaling of PI3–kinase but
elevated in many cancers where it suppresses tumor suppressor
genes. More recently, KRAS has also been associated with the
undifferentiated state of pancreatic cancer stem cells [61] and in
testicular germ cell tumors [62]. Like KRAS, HSPD1 plays active
roles in cell signaling processes and has been associated with
tumorigenesis. This heat shock protein is also associated with
regeneration in lower vertebrates and recently shown to be
controlled by two known regulators of pluripotency, LIN28 and
LET-7, (for review [63]) during retinal regeneration in zebrafish
[64]. Proteomic analyses have also detected elevated expression of
HSPD1 in mouse and human ESCs [65–69].
Discussion
This study is the first to report a comparative analysis of human
EGCs and PGCs with other pluripotent human stem cells. These
results demonstrate a unique pattern of expression for human
EGCs that is distinct from PGCs and other pluripotent stem cells.
Differences are also seen between human PGCs and EGCs with
their mouse counterparts. Specifically, this study identified 20
novel genes that were upregulated in all pluripotent stem cells
compared to PGCs and 78 genes upregulated specifically in EGCs.
These novel genes provide evidence for unique factors in germ
cells that may contribute to their developmental state and
potentially to the intermediate pluripotent state of EGCs. These
genes comprised a significant portion of regulators of the cell cycle,
DNA repair, and DNA recombination. This was supported by GO
analysis which demonstrated a substantial amount of energy
exerted in cell cycle and metabolic processes in the stem cell lines
Figure 7. Graphical representation of biological relationships in genes responsible for human embryonic stem cell pluripotency
detected by IPA analysis. Green color represents genes of the pathway that are up-regulated in the pluripotent stem cells compared to PGCs and
gray color represents genes that are expressed at similar levels between both groups. White signifies genes whose expression was not detected in
the cell lines.
doi:10.1371/journal.pone.0039088.g007
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the ESCs, IPSCs, and ECCs compared to EGCs.
Unique Features of the PGC and EGC Transcriptional
Program
Despite being committed to a single lineage, PGCs are unique
because they co-express many key pluripotent genes. Specifically,
we show here for the first time that human PGCs and EGCs show
quantitative differences in their expression of pluripotency
associated genes, SOX2 and DNMT3B, compared to other human
pluripotent stem cells. SOX2, together with OCT4 and NANOG,i s
required for ESC cell self-renewal and pluripotency (reviewed in
[70,71]) and for reprogramming somatic cells into IPSC cells [72].
Others have similarly reported that SOX2 protein is not expressed
in human PGCs [45]. Specifically, our data shows that human
PGCs express SOX2 transcript albeit at reduced levels (similar to
fibroblast cell lines) while it is significantly elevated in human
EGCs, IPSCs, ECCs and ESCs.
In contrast, DNMT3B levels in PGCs and EGCs were similar to
fibroblasts compared to elevated levels in the ESC, IPSC, and
Figure 8. Graphical representation of biological relationships in known or suspected genes associated with controlling cell cycle,
replication, DNA repair, recombination, and cell death. This network is specifically showing genes that are up-regulated in pluripotent stem
cells compared to PGCs. Green color represents genes in this network that are highly up-regulated in the ESC, IPSC, and ECC group and gray color
represents genes that are expressed in similar levels across all cell types. White signifies that the gene was not detected in the cell lines. Solid and
dotted arrows represent direct and indirect interactions, respectively. Elevated levels of KRAS and HSPD1 were also detected in EGCs.
doi:10.1371/journal.pone.0039088.g008
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its expression elevated in human ESCs [34,73]. DNMT3B has also
been identified as one of three genes critical to distinguishing the
fully reprogrammed state of pluripotent human ESCs and IPSCs
[74]. Here, we show for the first time considerably lower
expression of this gene in human PGCs and EGCs compared to
levels detected in ESCs, IPSCs, and ECCs further suggesting that
human EGCs exist in a unique pluripotent state and that reduced
DNMT3B expression may be a contributing factor for the unique
chromatin state of EGCs [75].
In addition to known markers of pluripotency, the analyses
performed here reveal unique factors of the germ cell lineage that
may also define the developmental potency of human PGCs and
EGCs. Specifically, this study found several genes that were highly
expressed in either human PGCs exclusively or also in EGCs
compared to other pluripotent stem cells suggesting their role in
regulating the unique states of these cell types. Genes upregulated
in PGCs alone included HBA1, SPANXA1, and DMRT1 while
genes upregulated in both PGCs and EGCs included EHD2,
ITGA8, epithelial membrane protein 1 (EMP1), and collagen, type I,
alpha 2 (COL1A2). These genes are interesting candidates for
future studies as other reports have either directly or indirectly
associated their elevated expression with the germ cell lineage yet
none have reported their role in regulating germline developmen-
tal potency. For instance, DMRT1, up regulated in human PGCs,
is a tumor suppressor gene with putative roles in regulating PGC
proliferation. The absence of Dmrt1 causes mice spermatogonia to
precociously exit the spermatogonial program and enter meiosis
[76]. It has also been shown to directly repress Sox2 expression in
mice and when down regulated increase teratoma formation.
Reduced expression has also been identified in human germ cell
tumors [77]. Thus, DMRT1 is a potential candidate for repressing
SOX2 expression in human PGCs. Likewise, EHD2, ITGA8 and
EMP1 has also been identified as tumor suppressor genes that
when altered is associated with highly malignant ovarian cancers
and germ cell tumors [62,78–81]. Likewise, we show elevated
expression of COL1A2 in human PGCs and EGCs similar to others
who have shown that COL1A2 distinguishes type A spermatogo-
nia stem cells from differentiated germ cells in mouse [82]. Thus,
genes found upregulated exclusively in PGCs in this study are
potential candidates involved in maintaining the unipotent state of
pre-meiotic, proliferative human PGCs while those upregulated in
PGCs and EGCs may play a role in maintaining a unique
pluripotent state of human EGCs.
Other genes that were among the most highly upregulated in
PGCs included 3 of 11 genes recently identified that distinguished
mouse PGCs from pluripotent germline stem cells. These genes
included germ cell specific proteins like TEX13 and meiotic
protein SPO11, as well as the hemoglobin protein, HBA1 [31].
Three other markers that were discussed in the report including,
Pik3r3, Mov10l1, and Fkbp6, were also differentially expressed in
our human cell populations. However, unlike mouse PGCs, where
these genes were upregulated, in human PGCs PIK3R3 and
FKBP6 expression was consistently down regulated compared to
human stem cells, and MOV10L1 was expressed at similar levels
between human PGCs and EGCs. While these results suggest
specie differences in their expression in human and mouse cells,
future confirmation is warranted.
Unique Features of the Stem Cell Transcriptional
Program
From the top most differentially expressed genes, several
candidates that may play a role in controlling pluripotency were
discovered. These genes were highly up regulated in EGCs,
IPSCs, ECCs and ESCs compared to PGCs and included genes
involved in chromatin remodeling such as IPO7, MED7, and
RBM26 as well as DNA repair and transcriptional activation such
as HSPD1 and KRAS. These candidates are particularly interesting
as recent evidence has shown roles for these factors in mechanisms
that facilitate pluripotency. For instance, one report has suggested
an important role of IPO7 in the nuclear import of Sox2 and high
mobility group (Hmg) box domain proteins in mouse ESCs [83]
which are two well-known regulators of stem cell self-renewal.
Another interesting candidate that is upregulated in EGCs
compared to PGCs was MED7. Mediator proteins, like MED7,
are known traditionally for their role as transcriptional co-
activators required for RNA polymerase II activity [72]. However,
mutations in MED7 have recently identified a novel role for MED7
in directly silencing subteleromic genes and increasing telomere
length and life span in Saccharomyces cerevisiae. This makes MED7 an
interesting candidate given that telomere activity is also known to
play a significant role in regulating pluripotency.
KRAS and HSPD1 play active roles in cell signaling processes.
Here we show for the first time their potential involvement in
establishing the pluripotent state of human stem cells as both genes
were among a few genes that were highly differentially expressed
in all stem cell lines compared to PGCs. The heat shock protein,
HSPD1, is known as a regeneration-associated gene in lower
vertebrates and recently shown to be controlled by two known
regulators of pluripotency, LIN28 and LET-7 [64], in zebrafish
[74]. Likewise, KRAS has also been shown to be repressed by LET-
7 in cancer cell lines resulting in reduced radio sensitivity [84].
This role of KRAS would make it consistent with a molecule that
is involved in contributing to the pluripotent stem cell phenotype
as stem cells are well known for their increased sensitivity to DNA
damage.
It is known that pluripotent stem cells have a distinct cell-cycle
from differentiated cells. They exhibit long-term proliferative
capacity by spending a proportionally shorter period of time in G1
and a proportionally longer period of time in S phase compared to
adult cells [85,86]. However, it is still unknown how these
distinguishing features contribute to the pluripotent state. Here, we
report for the first time differences in expression of cell cycle
components between human PGCs and pluripotent germline stem
cells which may implicate their role in defining the pluripotent
state. These included both G1 and G2 phase mediators such as
CCNB1, CCNG1, MAD2L1, Aurora kinase A (AURKA), HSPD1, and
KRAS. For instance, CCNE1 and CDK6 along with G1 checkpoint
mediator MAD2L1 were upregulated in ESCs, IPSCs, and ECCs
but not EGCs compared to PGCs. While a few studies have shown
the role of CYCLIN D and CYCLIN E in mediating the stem cell
phenotype of ESCs their role in maintaining the pluripotent state
of EGCs has not been studied [87–90]. Likewise, a similar pattern
of expression in constituents of the G2/M phase including CYCLIN
B, CYCLIN G and CDK1 along with G2/M checkpoint regulator
AURKA was also revealed to be upregulated in IPSCs, ECCs and
ESCs compared to EGCs. Thus, it remains unknown how
differences in G1 and G2 cell cycle contribute to the unique
pluripotent state of EGCs which appear more similar to PGCs in
their cell cycle expression than other pluripotent stem cells.
Links between pluripotency and self-renewal have been
established with examples of pluripotency associated genes
modulating key regulators of cell cycle and vice versa. For
example, SOX2(S) and OCT4 (O) through microRNAs, and
NANOG (N) has been shown to regulate G1 progression at the
transcription level [84]. Quantitative RT-PCR analysis performed
in this study specifically showed that human EGCs expressed
intermediate levels of these pluripotent genes and that SOX2 was
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discovering potential links between these three genes and how they
regulate the cell cycle may unravel key mechanisms involved in
germ cell reprogramming. Interestingly, two cell cycle regulators
potentially involved in the SON network MYCN and CYCLIN E
which have established roles in defining pluripotency in human
stem cells and which were down regulated in EGCs compared to
other human stem cell lines [91] are likely targets for contributing
to the EGC’s unique pluripotent state.
Important to the self-renewal of pluripotent stem cells is the
sensitivity of these cells to DNA damage. As stem cells give rise to
all cell types of the embryo, mutations incurred in early
development would be detrimental to an organism [11,92–96].
Thus, stem cells are hypersensitive to DNA damage [97] and as a
result, demonstrate more effective stress defense pathways than
more differentiated cell types. Examples of these mechanisms
include removing endogenous free radicals generated by their
increased proliferation [97,98] and greater efficiency in DNA
damage repair after radiation compared to their differentiated
counterparts [99]. Thus, pluripotent stem cells must elicit unique
responses to DNA repair and recombination. Our study reports
for the first time novel connections with key regulators of DNA
repair and recombination in regulating the pluripotent state
including KRAS and PARP1. When activated, KRAS suppresses
DNA repair-related tumor suppressor genes involved in homol-
ogous recombination (HRR) such as BRCA1, BRCA2, TP53, and
EXO1 [100]. Specifically, it has recently been shown that HRR is
the predominant DNA double-strand breaks (DSB) repair pathway
in mouse ESCs with minimal contributions by nonhomologous
end joining (NHEJ) and microhomology-mediated end joining
(MMEJ) repair mechanisms [101]. This is consistent with NHEJ
and MMEJ being more error-prone (reviewed in ref. [102–105])
and theoretically resulting in unsustainable mutations. In a similar
fashion, elevated expression of PARP1 in stem cells suggests that it
may also be associated with pluripotency. For instance, Poly
(ADP-ribose) polymerase proteins, like PARP1 are involved in a
number of cellular processes involving mainly in DNA repair and
programmed cell death and comparisons performed here support
data that have shown PARP1 is involved in the OCT4 and SOX2
network in mouse ESCs [24,44].
Conclusion
In conclusion, this study is the first to compare and analyze
global gene expression profiles of human EGCs and PGCs with
those of embryo-derived and germ-cell derived stem cells. The
results reveal distinct features regarding the transcriptional
programs of these cell types. Results from this study identified
sets of genes that characterize the developmental status of human
EGCs and PGCs from ECCs, IPSCs, and ESCs, and serve as
important genes to delineate germ cell lineages and pluripotency
in human cells. Furthermore, these findings provide important
data for identifying potential mechanisms required for the
reprogramming of unipotent primordial germ cells into the
pluripotent state. Comparisons of PGCs identified 20 genes that
are specifically upregulated in all stem cell types including EGCs
provides important information for distinguishing differential
pluripotent states in human germ cells and possibly conventional
ESCs and IPSCs as well.
Summary
In summary, differences in the transcriptional profiles and
signature genes across different stem cell types shown here are
consistent with multiple states of the pluripotency. In particular,
EGCs exhibit a genetic signature distinct from other pluripotent
stem cells which suggests that these stem cells are in a unique
pluripotent state. These factors include novel regulators of the cell
cycle, DNA repair and recombination. However, it remains to be
seen whether EGCs are more like naive mouse ESCs or whether
they represent a partially reprogrammed IPSC-like state. Alterna-
tively, differences in their genetic profiles would attribute to a
notion that not all pluripotency-associated genes are regulated in
the same way in all pluripotent stem cells, or that epistatic
interactions play a significant role in the defining pathways that
generate the undifferentiated state.
Materials and Methods
Collection of Tissue
Gonadal tissues, primordial germ cells and embryonic germ cell
lines were obtained from human fetuses 8–11 weeks post
fertilization as a result of termination of pregnancy, via protocols
and written patient consent, approved by the Joint Committee on
Clinical Investigation of the Johns Hopkins University School of
Medicine. Gestational age was confirmed by anatomical markers
which include limb and digit formation, crown heel and crown
rump measurement as well as the first day of the last maternal
menstrual cycle. Ages are discussed in terms of fetal development
and not the age from the last menstrual period. Sex of the tissue
was determined by gross morphological examination of the gonads
and by fluorescent in situ hybridization of tissue connected to the
gonads as previously performed [7,24].
Human PGC Acquisition and EGC Derivation
PGCs were isolated using magnetic cell sorting technology
(MACs) and indirect labeling of cells with magnetically tagged goat
anti-mouse IgM antibodies toward a mouse-anti-SSEA1 antibody
(Miltenyi Biotech). Briefly, gonads were minced in 1 mg/mL
collagenase, incubated at 37uC for 20 min, rinsed, and incubated
with SSEA1 antibody (1:5 dilution) for 15 min on ice. Afterward,
secondary antibody was applied at 1:100 dilution for another
30 min on ice and sorted on magnetic columns as previously
described [24,106,107]. SSEA1+ PGCs were either directly
prepared for microarray analyses or used to generate EGCs. For
EGC generation, SSEA1+ PGCs from a single gonad were sorted
and approximately 50 cells were seeded in each of 12 wells of a 96-
well plate with irradiated mouse embryonic feeder cells, SIM 6-
thioguanine resistant ouabain (STO) (,125,000 cells/well;
ATCC) [108]. Media consisted of Dulbecco’s modified Eagle’s
medium-199 (Invitrogen) supplemented with 20% Knockout
serum (Invitrogen), 2 ng/mL FGF2 (R&D Systems), 1000 U LIF
(Millipore), 10 mM forskolin, and 20 ng/ml BMP4 (R&D
Systems).
Human ESC Culture
Human ESCs from the H1 line (WiCell, Fed ID# 0043) were
cultured on matrigel (BD Biosciences) in 10-cm cell culture dishes
with Dulbecco’s modified Eagle’s medium/F12-Knockout serum-
based media conditioned by mouse embryonic fibroblast cells
(MEFs) (Millipore, Strain CF1) and supplemented with 4 ng/mL
FGF2 as described previously [108].
Human ECC Culture
The human embryonal carcinoma line NTERA-2 cl.D1 and
Tera-2 was acquired through American Type Culture Collection
(ATCC) (Virginia) and cultured on matrigel-coated plates under
conditions described previously for this cell line [109].
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HFF-1 line was acquired by ATCC (SCRC-1041) and is a
human fibroblast cell line originally derived from the foreskins of
two individuals [110]. Cells were grown in similar condition as
MEFs (Millipore, Strain CF1) in Dulbecco’s Modified Eagle’s
Medium, DMEM199 supplemented with 15% bovine serum
albumin.
IPSC Generation and Culture
All IPSC lines were derived from PGCs obtained by different
specimens. Lentiviral production were performed using Gate-
wayH-compatible cDNAs for SOX2, OCT4, and MYCN (Invitrogen)
inserted via recombination with LR Clonase into a modified
(attR1, attR2) pLVX-Puro vector (Clontech) using the GatewayH
recombination system (Invitrogen). Purified, high titer VSV-G
pseudo typed lentiviral preps for expression of each transgene were
prepared using standard methods. SSEA1+ PGCs were trans-
duced with replication-defective recombinant lentivirus for 12
hours at multiplicity of infections (MOI) of 5–10 for each construct
in the presence of 6 ug/ml Polybrene (Sigma).
Lentiviral expression was confirmed by qRT-PCR analysis with
transgene-specific primers. Transgenes were silenced three weeks
after lentiviral transfections. Pluripotency was confirmed by OCT4,
NANOG and SOX2 protein expression, differentiation assays and
teratoma formation assays in nude mice. Cells were maintained in
culture using methods described above for ESCs.
Micro-array Analysis
To analyze gene expression profiles, the Affymetrix Human
U133 Plus 2.0 GeneChip was used. RNA extraction, reverse
transcription, cRNA preparation, and chip hybridization were
performed according to the manufacturer’s instructions (Affyme-
trix, Santa Clara, CA). In brief, total RNA was extracted from
cultured cells using RNeasy (Qiagen, Valencia, CA) protocols
described below for RT-PCR. Five micrograms of purified RNA
were then used as a template for double-stranded cDNA synthesis
primed using a T7-(dT)24 oligonucleotide. Double-stranded
cDNA was then used as a template for biotin-labeled cRNA
preparation using T7 RNA polymerase. Biotinylated cRNA
(15 mg) was fragmented at 94uC for 35 minutes (100 mM Tris-
acetate pH 8.2, 500 mM potassium acetate, 150 mM magnesium-
acetate), and hybridized to the Affymetrix HG U133 Plus 2.0
GeneChips containing ,54,000 transcripts for 16 hours at 45uC
with constant rotation (60 rpm). An Affymetrix Fluidics Station
450 was used to remove the non-hybridized target and to incubate
with a streptavidin-phycoerythrin conjugate to stain the biotiny-
lated cRNA. The staining was amplified using goat IgG as
blocking reagent and biotinylated goat anti-streptavidin antibody,
followed by a second staining step with a streptavidin-phycoery-
thrin conjugate. Fluorescence was detected using the Affymetrix
G3000 GeneArray Scanner and image analysis of each GeneChip
was done through the GeneChip Operating System 1.4 (GCOS)
software from Affymetrix, using the standard default settings.
Statistical analyses of microarray data were performed using a
combination of bioconductor (http://www.bioconductor.org) and
Partek
TM software (Version 6.5) (http://www.partek.com). The
raw signal values were normalized with quantile normalization
method and gene level expression was summarized using RMA
(Robust Multi-Array) method [111]. Principal Component
Analysis (PCA) were performed using Partek
TM software and
differential gene expression were detected using bioconductor
package limma [112]. The FDR adjusted p value cutoff of
,0.0001 was used to obtain the lists of differentially expressed




RNA from EGCs, PGCs, ESCs, ECCs, and IPSCs were isolated
for quantitative real-time (qRT)–polymerase chain reaction (PCR)
using MiniRNeasy kits (Qiagen 74124) with the RNA clean-up
protocol and optional on-column DNase treatment. Complemen-
tary DNA was generated with SuperScript III First-Strand
Synthesis System RT Kits, following the manufacturer’s instruc-
tions (INV18080-051). Real-time qRT-PCR analysis was per-
formed using ABi7900HT with Taqman Assay-on-Demand
designed oligonucleotides for the detection of OCT4, SOX2,
NANOG and DNMT3B and each sample had a template equivalent
to 5 ng of total RNA (Table S1). Quantitation was measured
using the DDCt method and normalized to b-actin. Each primer
set was tested in at least triplicate across biological replicates.
Statistics
t-Tests were performed to evaluate the significance between two
groups. Significance was accepted at p,.05.
Gene Classification and Biosystem Modeling
The Ingenuity Pathway Analysis (IPA) program (http://www.
ingenuity.com) was used for pathway and gene classification
analysis of differentially expressed genes. The microarray data set
was translated into HUGO gene identifiers and uploaded to the
IPA system. The IPA software is a Java based online exploratory
tool with a curated database for genes with millions of published
literature references. The IPA database builds gene networks,
pathways, and biological function clusters. IPA software uses
published literature from the database to map the biological
relationship of the uploaded genes. Fisher’s exact test is used to
determine the probability that each biological function is due to
chance alone. Scores for IPA networks are the negative logarithm
of the p-values calculated. They indicate the likelihood of the focus
proteins in a network being found together due to random chance.
Scores of 2 or higher have at least a 99% likelihood of not being
generated by chance alone. Panther Classification System was
used to perform gene ontology analyses. This system uses the Gene
Ontology
TM (GO) platform to classify genes by biological process,
molecular function and cell components and includes commonly
used classes of protein functions many of which are not covered by
other GO analyses (www.pantherdb.org).
Data Access
Supplemental material will be provided at www.genome.org.
Raw microarray CEL files will be deposited in the GEO database
with accession numbers upon acceptance of the publication.
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Table S1 The real-time qRT-PCR analysis data for the
detection of OCT4, SOX2, NANOG and DNMT3B.
(XLS)
Table S2 Details of the cells used in this study.
(XLS)
Table S3 Data for PCA results including log ratio values
and P-values.
(XLSB)
Table S4 The most highly differentially expressed
genes (1000 of 54,000 or 1.85% genes in the array)
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